Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Generics
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Generics
Viatris has announced that the antitrust division of the US Department of Justice (DOJ) has concluded its investigation into Mylan and its former president, Rajiv Malik. 3 July 2024
Generics
An activist investor has renewed its effort to prevent Taro Pharmaceutical from accepting a buyout bid from Sun Pharmaceutical. 24 April 2024
Generics
Generic drugmaker Apotex has reached an agreement to acquire fellow Canada-based Searchlight Pharma. 5 April 2024
Generics
KELIX bio, an emerging markets biopharmaceuticals platform, has been sold to Mubadala Investment Company, an Abu Dhabi investor with over $276 billion in assets under management. 25 March 2024
Generics
Generic drugmaker Aspire Pharma today announced the successful completion of its acquisition of fellow UK-based Cenoté Pharma, in continuation of its strong organic growth. 11 March 2024
Generics
In a bid to focus on growth and innovation, Israeli generics drugmaker Teva Pharmaceutical is to hive off its active pharmaceutical ingredient (API) business. 1 February 2024
Generics
Sun Pharmaceutical Industries of India announced its intention to acquire all outstanding shares of US generics drugmaker Taro Pharmaceutical Industries at a price of $43 per share in cash, the companies announced. 19 January 2024
Generics
Taiwan’s Bora Pharmaceuticals is to acquire Upsher-Smith Laboratories, a US generics manufacturer. 17 January 2024
Generics
South Africa's largest drugmaker Aspen Pharmacare has announced an agreement with newly-independent generics drugmaker Sandoz, related to its Chinese business. 7 December 2023
Generics
Portuguese contract development and manufacturing organization (CDMO) Hovione has acquired the start-up ExtremoChem for an undisclosed amount. 20 November 2023
Generics
The Indian pharma and healthcare sector has witnessed a 298% jump in deals during the third quarter of 2023 compared to the same period last year. 8 November 2023
Generics
A confluence of factors is creating a conducive environment for mergers and acquisitions (M&As) to pick up pace in India. 23 October 2023
Generics
USA-based drugmaker Viatris has announced a series of divestitures as part of a strategy to narrow the company’s focus. 3 October 2023
Generics
Indian drugmaker Glenmark Pharmaceuticals has entered into a definitive agreement with Nirma Limited to divest a 75% stake in its subsidiary, Glenmark Life Sciences Limited (GLS), which focuses on producing active pharmaceutical ingredients (APIs). 22 September 2023
Generics
Shares of Hyderabad, India-headquartered Suven Pharmaceuticals hit a fresh 52-week high on the bourses after the Indian government gave the green signal to foreign direct investment (FDI) of up to $1.15 billion by drug major Cyprus-based Berhyanda. 19 September 2023
Generics
Several international investors and fund managers have expressed an interest in investing in the Indian pharmaceutical and biotechnology sectors, underlining the need to establish a platform to facilitate the transition of global capital flows into the domestic economy. 14 April 2023
Generics
In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block. A number of private equity firms have been approached, including Baring Private Equity, Bain Capital, Blackstone, Carlyle, and KKR. 19 December 2022
Generics
Generics major Viatris yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences. 8 November 2022
Generics
Private equity firm SK Capital Partners has entered into a deal to acquire Apotex Pharmaceutical Holdings, a Canada-based generic drugmaker with products across all major therapeutic areas for patients around the world. 29 September 2022
Generics
Indian drugmaker Sun Pharmaceuticals (SUN: BO) has proposed to acquire the remaining shares of Israel-based Taro Pharmaceutical (Pink Sheets: TAROF) for $24.50/share in cash representing a 26% premium over Taro's closing price on October 17, 2011 and/or 24% premium over closing price in the last 60 days. Sun Pharma currently holds around 66%, of Taro's 44,535,832 ordinary shares outstanding. 20 October 2011
Generics
Switzerland-based generic and branded drugmaker Acino (SIX: ACIN) says it has reached agreement to acquire the combined Middle East and African business of US biotech firm Cephalon, which just this month was acquired by Israel's Teva Pharmaceutical Industries (Nasdaq: TEVA; The Pharma Letter October 14), for a total consideration of around 80 million euros ($110.9 million). 18 October 2011
Generics
Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the US Federal Trade Commission has accepted the proposed consent order in connection with the pending $6.8 billion acquisition of US biotech firm Cephalon (Nasdaq: CEPH) by Teva, which outbid Canada's Valeant Pharmaceuticals for the company (The Pharma Letter March 3), and granted early termination of the Hart Scott Rodino waiting period. 10 October 2011
Generics
US niche generics maker Akorn (Nasdaq: AKRX) has entered into an agreement to acquire certain assets of Kilitch Drugs (KDIL), a contract manufacturer of sterile injectables in India, as well as certain assets of NBZ Pharma, for around $52 million in cash and future contingent payments totaling up to about $6 million based on the achievement of certain milestones and financial targets. 6 October 2011
Generics
Jordan-headquartered Hikma Pharmaceuticals (LSE: HIK) says that it has acquired 63.9% of Promopharm (Societe de Promotion Pharmaceutique du Maghreb; Casablanca: PRO) from a consortium of shareholders, comprising existing management, institutions and related parties, for an aggregate cash consideration of $111.2 million and will launch a mandatory tender offer for the remaining 36.1% of the company. 5 October 2011
Generics
Iceland-headquartered generic drugmaker Actavis Group last week started marketing olanzapine tablets, a copy version of US drug major Eli Lilly's (NYSE: LLY) blockbuster schizophrenia and bi-polar disorder drug Zyprexa, in Austria, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Romania, Sweden and the UK, immediately after the patents expired on September 26 and 27, respectively. 3 October 2011
Generics
Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA), the world's largest generic drugmaker, says that it will acquire the 50% interest formerly held by Japan's Kowa (TYO: 3117) in their Japanese joint venture for a total consideration of $150 million. With this acquisition, Teva will own 100% of the former JV, which will immediately begin to do business as an important and wholly-owned member of the Teva group. 27 September 2011
Generics
Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says it is exercising its option to make an additional $19 million investment in privately-held Israeli biotech firm CureTech, which specializes in developing cancer treatments, and to finance up to $50 million of the company's R&D program. 14 September 2011
Generics
Indian drugmaker Aurobindo Pharma (ARBN: BO) and OJSC Diod, a Russian manufacturer of ecological health care equipment and nutrition supplements, are setting up a 50:50 joint venture, to be named Aurospharma, to manufacture and sell generic pharmaceutical products in the markets of Russia, Belarus and Kazakhstan. 9 September 2011
Generics
Germany's DMV-Fonterra Excipients, a developer, producer and marketer of excipients to the pharmaceutical industry, has entered into an agreement to acquire the business and assets of Indian firm Brahmar Cellulose, a producer of pharmaceutical microcrystalline cellulose (MCC) and sodium carboxyl methyl cellulose (SCMC). 31 August 2011
Generics
Huddinge, Sweden-based infectious disease research specialist Medivir (OMX: MVIR) says it recently-acquired BioPhausia AB subsidiary has reached an agreement to sell its generics business ' the company's BMM Pharma AB unit - to Swedish firm Bluefish Pharmaceuticals AB for 26 million Swedish kronor ($4.1 million) plus the value of inventories, some 12 million kronor The staff of BMM Pharma will not transfer in the acquisition. 30 August 2011
Generics
Par Pharmaceutical (NYSE: PRX) has entered into a definitive agreement to acquire fellow USA-based Anchen Pharmaceuticals, a privately-held specialty drugmaker focused on developing and commercializing extended release and niche generic products, for $410 million in cash. The transaction, which is expected to complete by year-end, is expected to be immediately accretive to non-GAAP earnings in 2011. 25 August 2011
Generics
US specialty pharma company Akorn (Nasdaq: AKRX), has entered into an agreement to acquire an unspecified minority stake in Westborough, Massachusetts-based Aciex Therapeutics an ophthalmic drug development company with a focus on developing novel therapeutics to treat ocular diseases. 4 August 2011
Generics
US generics drugmaker Perrigo (Nasdaq: PRGO;TASE) say that it has closed its $540 million cash acquisition of Paddock Laboratories, a Minneapolis-based pharmaceutical manufacturer of generic prescription drugs and over-the-counter specialty products (The Pharma Letter January 21). 28 July 2011
Generics
Generics company Dr Reddy's Laboratories (NYSE: RDY), India's second largest drugmaker, has entered into an agreement with JB Chemicals & Pharmaceuticals to acquire their pharmaceutical prescription portfolio in the Russia and other Commonwealth of Independent States (CIS) regions. 25 July 2011
Generics
Fast-growing Jordan-headquartered drugmaker Hikma Pharmaceuticals (LSE: HIK) says that it has acquired a 'significant,' but undiscosed minority interest in China-based Hubei Haosun Pharmaceutical through the subscription of new equity for a cash consideration of $5.0 million. 11 July 2011
Generics
Both multinationals drugmakers and large domestic players are set to grab a larger share of the pharmaceutical market in China, as health care reforms start to play an increasingly important role, according to a recent report from financial consultants KPMG titled China's pharmaceutical industry - poised for the giant leap. 22 June 2011
Generics
The Indian pharmaceutical industry is moving towards the adoption and development of generic drugs, which will help it to grow at a compound annual growth rate (CAGR) of around 15% during the fiscal years 2012 through 2014, according to a new report from market research group RNCOS. 21 June 2011
Generics
USA-based K-V Pharmaceutical (NYSE: KVa/KVb) has entered into a definitive agreement to divest Nesher Pharmaceuticals, its generics subsidiary, as well as the company's generic business and assets to Zynesher Pharmaceuticals, a US unit of India's Zydus Cadila, for around $60 million in cash. The transaction is expected to close during the second quarter of KV's 2012 fiscal year, subject to customary closing conditions. 20 June 2011
Generics
The world's largest pharma company, USA-based Pfizer (NYSE: PFE), has entered into a memorandum of understanding with leading Chinese drugmaker and Zhejiang Hisun Pharmaceuticals (SSE: 600267), on their intention to establish a joint venture. This potential partnership would aim to strengthen the ability of both companies to reach more patients with high-quality and low-cost medicines in the branded generics arena. 3 June 2011
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze